These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 16424403)
1. COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1. Celli B Chest; 2006 Jan; 129(1):5-6. PubMed ID: 16424403 [No Abstract] [Full Text] [Related]
2. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Rennard SI; Schachter N; Strek M; Rickard K; Amit O Chest; 2006 Jan; 129(1):56-66. PubMed ID: 16424413 [TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 4 inhibitors: antiinflammatory therapy for chronic obstructive pulmonary disease at last? Kerstjens HA; Timens W Am J Respir Crit Care Med; 2003 Oct; 168(8):914-5. PubMed ID: 14555456 [No Abstract] [Full Text] [Related]
5. [Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases]. Xia XD; Dai YR; Xu ZJ Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jan; 27(1):57-9. PubMed ID: 14989829 [No Abstract] [Full Text] [Related]
10. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. Giembycz MA Br J Clin Pharmacol; 2006 Aug; 62(2):138-52. PubMed ID: 16842388 [TBL] [Abstract][Full Text] [Related]
11. The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients. Ouagued M; Martin-Chouly CA; Brinchault G; Leportier-Comoy C; Depincé A; Bertrand C; Lagente V; Belleguic C; Pruniaux MP Pulm Pharmacol Ther; 2005; 18(1):49-54. PubMed ID: 15607127 [TBL] [Abstract][Full Text] [Related]